Search
Esmolol
go.drugbank.com/drugs/DB00187ApprovedInvestigationalWithdrawnEsmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. … It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses.
Ceftolozane
go.drugbank.com/drugs/DB09050ApprovedInvestigationalCeftolozane is a semi-synthetic broad-spectrum fifth generation cephalosporin. … [L6685] It was approved by the FDA in 2014 for use in combination with [Tazobactam] for the treatment of serious infections, such as intra-abdominal infections and complicated urinary tract infections.
Palbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalIt is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. … Palbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-oneAlfuzosin
go.drugbank.com/drugs/DB00346Approved[L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251] … Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow.
Products: ALFUZOSIN 5MG 1A PHARMA, ALFUZOSIN 10MG 1A PHARMAMethotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[L7180] Methotrexate was granted FDA approval on 7 December 1953.[L7198] … Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis.
Categories: OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: Methotrexate PF/sa Injection, METOTREXATO DOC GENERICISetmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327]
Momelotinib
go.drugbank.com/drugs/DB11763ApprovedInvestigationalMomelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. … [A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis.
Givinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigationalGivinostat is a small molecule histone deacetylase (HDAC) inhibitor. … It has been investigated as a treatment for a variety of inflammatory diseases, like Crohn's disease and juvenile idiopathic arthritis, cancers like leukemia and lymphoma, as well as several muscular dystrophies
Acoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigational[A264768] Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis. … Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis.
Copper gluconate
go.drugbank.com/drugs/DB11246ApprovedInvestigationalCopper gluconate is a copper salt of D-gluconic acid that displays a light blue to bluish-green color. … According to the good manufacturing or feeding practice by the FDA, copper gluconate is used as a nutrient or dietary supplement and is generally recognized as safe for use at a level not exceeding 0.005
Mixtures: Vitamin A C E W.niacinam.beta Car.and Min.